All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 1.4 [1.23, 1.6]
41 studies · 41 participants
Very low
OR 1.7 [1.38, 2.09]
17 studies · 17 participants
Low
OR 1.22 [1.03, 1.45]
24 studies · 24 participants
Very low
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
It is very uncertain whether inhaled corticosteroids changes BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Open‐label use of systemic corticosteroids · preterm infants
It is very uncertain whether inhaled corticosteroids changes open‐label use of systemic corticosteroids compared with placebo (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
BPD (36 weeks' PMA) · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids probably leads to lower BPD (36 weeks' PMA) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to lower mortality or BPD at 36 weeks' PMA compared with placebo or no treatment (high certainty).
1 finding from 1 review
Gastrointestinal perforation during primary hospitalisation · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher gastrointestinal perforation during primary hospitalisation compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids leads to higher cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Death or cerebral palsy · preventing bronchopulmonary dysplasia in preterm infants
Early systemic postnatal corticosteroids showed no clear difference in mortality or cerebral palsy at latest reported age compared with placebo or no treatment (high certainty).
1 finding from 1 review
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review